Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Microbiol Res ; 265: 127202, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36167007

RESUMEN

Uropathogenic Escherichia coli (UPEC) is the primary cause of urinary tract infections (UTIs) in animals and humans. We applied Transposon-Directed Insertion Site sequencing (TraDIS) to determine the fitness genes in two well-characterized UPEC strains, UTI89 and CFT073, in order to identify fitness factors during UTI in a pig model. This novel animal model better reflects the course of UTI in humans than the commonly used mouse model, and facilitates the differentiation between sessile and planktonic UPEC populations. A total of 854 and 483 genes in UTI89 and CFT073, respectively, were predicted to contribute to growth in pig urine, and 1257 and 764, were scored as required for colonization of the bladder. The combined list of fitness genes for growth in urine and cystitis contained 741 (UTI89) and 439 (CFT073) genes. The essential genes for growth on LB agar media supplemented with kanamycin and the fitness factors during growth in human urine were also analyzed in CFT073. A total of 457 essential genes were identified and the pool of fitness genes for growth in human urine included 215 genes. The gene rfaG, which is involved in lipopolysaccharide biosynthesis, was included in all the fitness-gene-lists and was further confirmed to be relevant for all the conditions tested regardless of the host and the strain. Thus, this gene may represent a promising target for the development of new therapeutic strategies against UTI UPEC-associated. Besides this important observation, the study revealed strain-specific differences in gene-essentiality as well as in the fitness-gene-repertoire for growth in human urine and UTI of the pig model, and it identified novel factors required for UPEC-induced UTIs.


Asunto(s)
Infecciones por Escherichia coli , Proteínas de Escherichia coli , Infecciones Urinarias , Escherichia coli Uropatógena , Agar , Animales , Modelos Animales de Enfermedad , Infecciones por Escherichia coli/veterinaria , Proteínas de Escherichia coli/genética , Humanos , Kanamicina , Lipopolisacáridos , Ratones , Porcinos , Escherichia coli Uropatógena/genética
2.
Microb Genom ; 7(12)2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34928200

RESUMEN

Uropathogenic Escherichia coli (UPEC) UTI89 is a well-characterized strain, which has mainly been used to study UPEC virulence during urinary tract infection (UTI). However, little is known on UTI89 key fitness-factors during growth in lab media and during UTI. Here, we used a transposon-insertion-sequencing approach (TraDIS) to reveal the UTI89 essential-genes for in vitro growth and fitness-gene-sets for growth in Luria broth (LB) and EZ-MOPS medium without glucose, as well as for human bacteriuria and mouse cystitis. A total of 293 essential genes for growth were identified and the set of fitness-genes was shown to differ depending on the growth media. A modified, previously validated UTI murine model, with administration of glucose prior to infection was applied. Selected fitness-genes for growth in urine and mouse-bladder colonization were validated using deletion-mutants. Novel fitness-genes, such as tusA, corA and rfaG; involved in sulphur-acquisition, magnesium-uptake, and LPS-biosynthesis, were proved to be important during UTI. Moreover, rfaG was confirmed as relevant in both niches, and therefore it may represent a target for novel UTI-treatment/prevention strategies.


Asunto(s)
Bacteriuria/microbiología , Medios de Cultivo/química , Cistitis/microbiología , Genes Esenciales , Glucosa/administración & dosificación , Análisis de Secuencia de ADN/métodos , Escherichia coli Uropatógena/crecimiento & desarrollo , Animales , Técnicas Bacteriológicas , Proteínas de Escherichia coli/genética , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Aptitud Genética , Glucosa/química , Glucosa/farmacología , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Ratones , Mutagénesis Insercional , Escherichia coli Uropatógena/clasificación , Escherichia coli Uropatógena/genética , Factores de Virulencia/genética
3.
Artículo en Inglés | MEDLINE | ID: mdl-29450193

RESUMEN

Most bacterial infections initiate at the mucosal epithelium lining the gastrointestinal, respiratory, and urogenital tracts. At these sites, bacterial pathogens must adhere and increase in numbers to effectively breach the outer barrier and invade the host. If the bacterium succeeds in reaching the bloodstream, effective dissemination again requires that bacteria in the blood, reestablish contact to distant endothelium sites and form secondary site foci. The infectious potential of bacteria is therefore closely linked to their ability to adhere to, colonize, and invade epithelial and endothelial surfaces. Measurement of bacterial adhesion to epithelial cells is therefore standard procedure in studies of bacterial virulence. Traditionally, such measurements have been conducted with microtiter plate cell cultures to which bacteria are added, followed by washing procedures and final quantification of retained bacteria by agar plating. This approach is fast and straightforward, but yields only a rough estimate of the adhesive properties of the bacteria upon contact, and little information on the ability of the bacterium to colonize these surfaces under relevant physiological conditions. Here, we present a method in which epithelia/endothelia are simulated by flow chamber-grown human cell layers, and infection is induced by seeding of pathogenic bacteria on these surfaces under conditions that simulate the physiological microenvironment. Quantification of bacterial adhesion and colonization of the cell layers is then performed by in situ time-lapse fluorescence microscopy and automatic detection of bacterial surface coverage. The method is demonstrated in three different infection models, simulating Staphylococcus aureus endothelial infection and Escherichia coli intestinal- and uroepithelial infection. The approach yields valuable information on the fitness of the bacterium to successfully adhere to and colonize epithelial surfaces and can be used to evaluate the influence of specific virulence genes, growth conditions, and antimicrobial treatment on this process.


Asunto(s)
Infecciones Bacterianas/microbiología , Carga Bacteriana/métodos , Fenómenos Fisiológicos Bacterianos , Membrana Mucosa/microbiología , Adhesión Bacteriana , Células Cultivadas , Células Epiteliales/microbiología , Tracto Gastrointestinal/microbiología , Humanos , Modelos Teóricos , Escherichia coli Shiga-Toxigénica/fisiología , Staphylococcus aureus/fisiología
4.
PLoS One ; 12(3): e0173362, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28278183

RESUMEN

INTRODUCTION: Conservative treatment solutions against aortic prosthetic vascular graft infection (APVGI) for inoperable patients are limited. The combination of antibiotics with antibacterial helper compounds, such as the neuroleptic drug thioridazine (TDZ), should be explored. AIM: To investigate the efficacy of conservative systemic treatment with dicloxacillin (DCX) in combination with TDZ (DCX+TDZ), compared to DCX alone, against early APVGI caused by methicillin-sensitive Staphylococcus aureus (MSSA) in a porcine model. METHODS: The synergism of DCX+TDZ against MSSA was initially assessed in vitro by viability assay. Thereafter, thirty-two pigs had polyester grafts implanted in the infrarenal aorta, followed by inoculation with 106 CFU of MSSA, and were randomly administered oral systemic treatment with either 1) DCX or 2) DCX+TDZ. Treatment was initiated one week postoperatively and continued for a further 21 days. Weight, temperature, and blood samples were collected at predefined intervals. By termination, bacterial quantities from the graft surface, graft material, and perigraft tissue were obtained. RESULTS: Despite in vitro synergism, the porcine experiment revealed no statistical differences for bacteriological endpoints between the two treatment groups, and none of the treatments eradicated the APVGI. Accordingly, the mixed model analyses of weight, temperature, and blood samples revealed no statistical differences. CONCLUSION: Conservative systemic treatment with DCX+TDZ did not reproduce in vitro results against APVGI caused by MSSA in this porcine model. However, unexpected severe adverse effects related to the planned dose of TDZ required a considerable reduction to the administered dose of TDZ, which may have compromised the results.


Asunto(s)
Dicloxacilina/farmacología , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/fisiología , Tioridazina/farmacología , Injerto Vascular/efectos adversos , Animales , Temperatura Corporal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Dicloxacilina/efectos adversos , Dicloxacilina/uso terapéutico , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Femenino , Haptoglobinas/metabolismo , Hemoglobinas/metabolismo , Recuento de Leucocitos , Infecciones Estafilocócicas/sangre , Infecciones Estafilocócicas/metabolismo , Staphylococcus aureus/efectos de los fármacos , Porcinos , Tioridazina/efectos adversos , Tioridazina/uso terapéutico , Factores de Tiempo
5.
J Control Release ; 241: 125-134, 2016 11 10.
Artículo en Inglés | MEDLINE | ID: mdl-27663229

RESUMEN

Approximately half of all nosocomial bloodstream infections are caused by bacterial colonization of vascular catheters. Attempts have been made to improve devices using anti-adhesive or antimicrobial coatings; however, it is often difficult to bind coatings stably to catheter materials, and the low amounts of drug in thin-film coatings limit effective long-term release. Interpenetrating polymer networks (IPNs) are polymer hybrid materials with unique drug release properties. While IPNs have been extensively investigated for use in tablet- or capsule-based drug delivery systems, the potential for use of IPNs in drug release medical devices remains largely unexplored. Here, we investigated the use of silicone-hydrogel IPNs as a catheter material to provide slow anti-bacterial drug-release functionality. IPN catheters were produced by the sequential method, using supercritical CO2 as a solvent to polymerize and crosslink poly(2-hydroxyethyl methacrylate) (PHEMA) in silicone elastomer. The design was tested against Staphylococcus aureus colonization after loading with dicloxacillin (DCX) alone or in combination with thioridazine (TDZ), the latter of which is known to synergistically potentiate the antibacterial effect of DCX against both methicillin-sensitive and methicillin-resistant S. aureus. The hydrophilic PHEMA component allowed for drug loading in the catheters by passive diffusion and provided controlled release properties. The drug-loaded IPN material inhibited bacterial growth on agar plates for up to two weeks and in blood cultures for up to five days, and it withstood 24h of seeding with resilient biofilm aggregates. The combined loading of DCX+TDZ enhanced the antibacterial efficiency in static in vitro experiments, although release analyses revealed that this effect was due to an enhanced loading capacity of DCX when co-loaded with TDZ. Lastly, the IPN catheters were tested in a novel porcine model of central venous catheter-related infection, in which drug-loaded IPN catheters were found to significantly decrease the frequency of infection.


Asunto(s)
Antibacterianos/farmacología , Infecciones Relacionadas con Catéteres/prevención & control , Polímeros/química , Infecciones Estafilocócicas/prevención & control , Staphylococcus aureus/efectos de los fármacos , Dispositivos de Acceso Vascular/microbiología , Antibacterianos/química , Infecciones Relacionadas con Catéteres/microbiología , Infección Hospitalaria , Dicloxacilina/química , Dicloxacilina/farmacología , Sistemas de Liberación de Medicamentos , Liberación de Fármacos , Polihidroxietil Metacrilato/química , Siliconas/química , Infecciones Estafilocócicas/microbiología , Tioridazina/química , Tioridazina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA